BlackRock, Inc. filed Amendment No. 3 to a Schedule 13G with the SEC on October 27, 2026, disclosing its beneficial ownership position in Novartis AG as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 145,227,650 shares of Novartis AG common stock, representing 7.1% of the class.
  • Sole voting power: BlackRock disclosed sole voting power over 132,888,846 shares, with zero shares subject to shared voting power.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 145,227,650 shares, with no shared dispositive power.
  • Event date: The filing event that triggered this statement was September 30, 2026.
  • Reporting person type: BlackRock is classified as a parent holding company (HC), organized in Delaware, with its principal business office at 50 Hudson Yards, New York, NY 10001.
  • No single outside interest exceeds 5%: According to the filing, no one person's interest in the common stock of Novartis AG is more than five percent of the total outstanding common shares.

BlackRock's Amended Beneficial Ownership Position in Novartis AG Common Stock

BlackRock, Inc. filed Amendment No. 3 to Schedule 13G on October 27, 2026, reporting its holdings in Novartis AG (CUSIP H5820Q150) as of September 30, 2026. According to the filing, BlackRock beneficially owned 145,227,650 shares of Novartis AG common stock, equal to 7.1% of the class. The filing was signed by Spencer Fleming, Managing Director, on behalf of BlackRock, Inc.

The filing states that BlackRock holds sole voting power over 132,888,846 shares and sole dispositive power over the full 145,227,650 shares. Shared voting power and shared dispositive power are each reported as zero. The filing notes, in accordance with SEC Release No. 34-39538 (January 12, 1998), that this Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it does not include securities beneficially owned by other business units whose ownership is disaggregated from the Reporting Business Units under that release.

Regarding third-party interests, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Novartis AG," but states that no individual person's interest exceeds five percent of the total outstanding common shares. BlackRock certified that the reported securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. filed Amendment No. 3 to Schedule 13G disclosing 145,227,650 shares, or 7.1%, of Novartis AG common stock beneficially owned as of September 30, 2026, with sole voting power over 132,888,846 shares and full sole dispositive power.